A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis.
Teraki
Y
Y
Tanaka
S
S
Hitomi
K
K
Izaki
S
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D003879:Dermatologic Agents / Q000009:adverse effects*; D003875:Drug Eruptions; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000069285:Infliximab; D020381:Interleukin-17 / Q000097:blood; D007378:Interleukins / Q000097:blood; D008875:Middle Aged; D010641:Phenotype; D011565:Psoriasis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D016201:Receptors, Lymphocyte Homing / Q000276:immunology*; D058504:Th17 Cells / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000097043:Interleukin-22
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab; D020381:Interleukin-17; D007378:Interleukins; D016201:Receptors, Lymphocyte Homing; D014409:Tumor Necrosis Factor-alpha; D000097043:Interleukin-22